Ming-Wei Chen and Fanheng Zhou, the scientists behind RephImmune, join hosts Lynnsey and Matthew to discuss how their biotech startup is developing a next-generation cell therapy platform designed to overcome the limitations of CAR-T. With a focus on ovarian cancer, RephImmune’s RACE-T technology targets solid tumors by re-engineering immune cells to better locate, penetrate, and survive in the harsh tumor environment.
Massachusetts Gov. Maura Healey blasted Robert F. Kennedy Jr. and other federal officials after the Centers for Disease Control and Prevention's website was changed to contradict the longtime scie...